AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24558033
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose naltrexone (0.1 mg/kg, maximum 4.5 mg/day) for 8 weeks in children
Trial: 24558033
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose naltrexone and placebo
Trial: 24559321
Drug: Intravenous anidulafungin
RxNorm normalized name: Anidulafungin
DrugBank: Anidulafungin (DB00362)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous anidulafungin followed by oral azole therapy (fluconazole or voriconazole) after 5 days if criteria met
Trial: 24559321
Drug: Early switch
RxNorm normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early switch to oral azole therapy (≤ 7 days' anidulafungin)
Trial: 24559321
Drug: Intravenous anidulafungin
RxNorm normalized name: Anidulafungin
DrugBank: Anidulafungin (DB00362)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous anidulafungin followed by oral azole therapy
Trial: 24559465
Drug: Urinary [TIMP-2]·[IGFBP7]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urinary [TIMP-2]·[IGFBP7] greater than 0.3 (ng/ml)(2)/1,000
Trial: 24561146
Drug: Recovery of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recovery of normal LV function and size after treatment
Trial: 24562448
Drug: Neoadjuvant chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemoradiotherapy with docetaxel (40 mg/m²), cisplatin (40 mg/m²), and panitumumab (6 mg/kg) with radiation therapy (5040 cGy, 180 cGy/day × 28 days) starting week 5.
Trial: 24562641
Drug: FDG PET/CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDG PET/CT during radiotherapy (mean dose 43 Gy)
Trial: 24563078
Drug: Continuous-infusion topotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous-infusion topotecan (0.4 mg/m² per day for 9-10 days every 3 weeks) with erlotinib (150 mg orally on days 1-10 of each cycle)
Trial: 24563078
Drug: Continuous-infusion topotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous-infusion topotecan with erlotinib
Trial: 24563480
Drug: PM01183 (4.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PM01183 (4.0 mg/m(2) recommended dose)
Trial: 24563480
Drug: PM01183 (7.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PM01183 (7.0 mg flat dose)
Trial: 24563480
Drug: PM01183 (recommended
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PM01183 (recommended dose)
Trial: 24563480
Drug: PM01183 (at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PM01183 (at or above recommended dose)
Trial: 24563781
Drug: Duloxetine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine treatment for 12 weeks
Trial: 24564178
Drug: CRP levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRP levels in patients without diabetes mellitus who are not receiving statin therapy
Trial: 24564281
Drug: MRI in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRI in CF patients with exacerbations before treatment
Trial: 24564281
Drug: MRI in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRI in CF patients with exacerbations after antibiotic therapy
Trial: 24565221
Drug: Saxagliptin 2.5
RxNorm normalized name: sAXagliptin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saxagliptin 2.5 mg BID plus metformin
Trial: 24566706
Drug: PF-03446962 10
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PF-03446962 10 mg/Kg intravenously fortnightly until disease progression or unacceptable toxicity
Trial: 24566733
Drug: Aspirin 100
RxNorm normalized name: aspirin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 100 mg once daily for 2 and 4 weeks
Trial: 24568177
Drug: Ziprasidone 40-160
RxNorm normalized name: ziprasidone 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziprasidone 40-160 mg/day
Trial: 24569099
Drug: Once-daily perphenazine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily perphenazine dosing
Trial: 24573552
Drug: Ultra low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ultra low-dose IL-2 (100,000-200,000 IU/m(2) ×3 per week for 6 to 12 weeks)
Trial: 24573552
Drug: Ultra low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ultra low-dose IL-2
Trial: 24574239
Drug: Ipilimumab, an
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipilimumab, an antagonist of CTLA-4
Trial: 24576165
Drug: T-BiRD regimen
RxNorm normalized name: Bird pepper
DrugBank: Bird pepper (DB14262)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T-BiRD regimen (thalidomide 100 mg/day, lenalidomide 25 mg/day, dexamethasone 40 mg/day, clarithromycin 500 mg twice daily)
Trial: 24576311
Drug: Sunitinib (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib (50 mg/day for 4 weeks, followed by 2 weeks off treatment in repeated 6-week cycles)
Trial: 24576794
Drug: Levonorgestrel (LNG)
RxNorm normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levonorgestrel (LNG) 150 mcg/ethinyl estradiol (EE) 20 mcg for 42 days, LNG 150 mcg/EE 25 mcg for 21 days, LNG 150 mcg/EE 30 mcg for 21 days and EE 10 mcg for 7 days
Trial: 24576794
Drug: Levonorgestrel/ethinyl estradiol
RxNorm normalized name: levonorgestrel/ethinyl estradiol 0.1 mg-20 mcg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levonorgestrel/ethinyl estradiol combined oral contraceptive
Trial: 24581956
Drug: Flexible insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flexible insulin therapy (FIT) educational programme
Trial: 24582505
Drug: Vemurafenib 960
RxNorm normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vemurafenib 960 mg orally twice a day
Trial: 24582522
Drug: Live-donor uterus
RxNorm normalized name: Oryctolagus cuniculus uterus preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live-donor uterus transplantation (UTx) with low-dose induction immunosuppression
Trial: 24583293
Drug: Hourly sampling
RxNorm normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hourly sampling of cTnT
Trial: 24583795
Drug: MK-2206 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-2206 (200 mg weekly)
Trial: 24587068
Drug: Psycho-educational intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Psycho-educational intervention delivered by peer health workers (PHW); included a computer-assisted pre-test, educational video session, and a 6-week group program with weekly meetings.
Trial: 24587318
Drug: Individual depressive
RxNorm normalized name: Nerve depressants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual depressive symptoms (e.g., sad mood, concentration problems)
Trial: 24589294
Drug: Etravirine 5.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etravirine 5.2 mg/kg (maximum dose 200 mg) twice a day (bid) plus optimized background regimen (OBR)
Trial: 24589294
Drug: Etravirine 5.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etravirine 5.2 mg/kg bid plus OBR
Trial: 24590637
Drug: Nivolumab (intravenous,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (intravenous, every 2 weeks for up to 96 weeks)
Trial: 24590653
Drug: High levels
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High levels of TH, PHOX2B, or DCX mRNA in BM after induction therapy
Trial: 24590653
Drug: Magnitude of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnitude of reduction in mRNA level between diagnosis and postinduction therapy in BM or PB
Trial: 24590680
Drug: bovine lactoferrin
RxNorm normalized name: Bovine lactoferrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bovine lactoferrin (bLf) 100 mg twice a day
Trial: 24590680
Drug: ferrous sulphate
RxNorm normalized name: Ferrous sulphate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ferrous sulphate 520 mg once a day
Trial: 24593248
Drug: Initial antibiotic
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial antibiotic treatment modification (n = 589; 28.9%)
Trial: 24593248
Drug: No initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No initial antibiotic treatment modification
Trial: 24593819
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g Osteoset® T with 4% tobramycin sulfate
Trial: 24593819
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g Osteoset® T with 4% tobramycin sulfate
Trial: 24593819
Drug: Osteoset® T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteoset® T (10 g, 30 g, and 50 g)
Trial: 24594870
Drug: Tenofovir disoproxil
RxNorm normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tenofovir disoproxil fumarate (TDF) 300 mg once daily for 48 weeks
Trial: 24595069
Drug: Oramorph (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oramorph (5 mg every 6 hours)
Trial: 24595454
Drug: GIP regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GIP regimen (gemcitabine 1000 mg/m² on days 1 and 5, ifosfamide 1200 mg/m²/day on days 1-5, cisplatin 20 mg/m²/day on days 1-5, granulocyte colony-stimulating factor 263 μg/day on days 7-15, repeated every 3 weeks for four cycles)
Trial: 24595628
Drug: Insulin analog
RxNorm normalized name: insulin analog, glargine 300 UNT Pen Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin analog therapy
Trial: 24595628
Drug: End-of-study hypoglycemia
RxNorm normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: End-of-study hypoglycemia (insulin-naive group)
Trial: 24598452
Drug: 5 million
RxNorm normalized name: colistin 1.5 million UNT Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 million EBV-CTLs/kg (1-3 doses)
Trial: 24598881
Drug: Breast milk
RxNorm normalized name: BREAST MILK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breast milk zinc concentration and total milk volume measured using deuterium oxide dose-to-mother tracer technique.
Trial: 24598881
Drug: Breast milk
RxNorm normalized name: BREAST MILK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breast milk zinc transfer measured using deuterium oxide dose-to-mother tracer technique.
Trial: 24602182
Drug: Pegloticase 8
RxNorm normalized name: pegloticase 8 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegloticase 8 mg IV every 3 weeks
Trial: 24603117
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg oral treprostinil TID for 7 days
Trial: 24603218
Drug: Gradient Gel
DrugBank: Flunarizine (DB04841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gradient Gel Electrophoresis (GGE)
Trial: 24606093
Drug: Metformin extended
RxNorm normalized name: metFORMIN Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin extended release 1500 mg/d for 12 weeks
Trial: 24606096
Drug: No Growth
RxNorm normalized name: Mechano growth factor
DrugBank: Mecasermin (DB01277)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: No Growth Hormone (GH) treatment (Control)
Trial: 24606567
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg oral dose of trametinib
Trial: 24606567
Drug: 5 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 μg radiolabelled i.v. microdose of trametinib
Trial: 24606768
Drug: Sunitinib 37.5
RxNorm normalized name: sunitinib 37.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 37.5 mg/day plus trastuzumab (loading, 4 mg/kg; then weekly 2 mg/kg or loading, 8 mg/kg; then 3-weekly 6 mg/kg)
Trial: 24606768
Drug: Sunitinib 37.5
RxNorm normalized name: sunitinib 37.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 37.5 mg/day plus trastuzumab
Trial: 24607242
Drug: Oral baclofen
RxNorm normalized name: Baclofen
DrugBank: Baclofen (DB00181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral baclofen (titrated from 2.5 mg 3 times a day to a maximum of 20 mg 4 times a day)
Trial: 24607558
Drug: Median time
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Median time from initiation of chemotherapy to CDI
Trial: 24610431
Drug: Medication (sertraline;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication (sertraline; SRT)
Trial: 24610431
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of CBT and medication (COMB)
Trial: 24613995
Drug: Mexiletine administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mexiletine administration to a carrier of the p.A997T-NaV1.5 mutation (1 individual)
Trial: 24614108
Drug: Gemcitabine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine infusion during PDAC resection
Trial: 24614178
Drug: Sequential radioembolization-sorafenib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential radioembolization-sorafenib therapy (sorafenib 400 mg twice-daily initiated 14 days post-radioembolization with yttrium-90 resin microspheres).
Trial: 24614178
Drug: Sequential radioembolization-sorafenib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential radioembolization-sorafenib therapy (sorafenib 600 mg median dose/day for a median duration of 4.1 months).
Trial: 24614178
Drug: Sequential radioembolization-sorafenib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential radioembolization-sorafenib therapy (with 90Y-microspheres).
Trial: 24614383
Drug: Rifapentine (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifapentine (doses ranging from 450 to 1800 mg)
Trial: 24614383
Drug: Rifapentine (once-daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifapentine (once-daily dosing over 14 days)
Trial: 24614383
Drug: Divided dosing
RxNorm normalized name: Aluminum Zirconium Trichlorohydrex Gly 20 g in 100 g TOPICAL STICK [Dividends]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Divided dosing of rifapentine
Trial: 24614947
Drug: Gemcitabine (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine (1,000 mg/m²) plus Cisplatin (25 mg/m²) on days 1 and 8, every 3 weeks for up to 24 weeks
Trial: 24615778
Drug: Idelalisib (50-350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idelalisib (50-350 mg daily or twice daily)
Trial: 24616310
Drug: Mogamulizumab (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mogamulizumab (1.0 mg/kg) administered intravenously once per week for 8 weeks
Trial: 24617713
Drug: Vandetanib (tyrosine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vandetanib (tyrosine kinase inhibitor)
Trial: 24618504
Drug: Magnetically guided
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnetically guided capsule gastroscopy
Trial: 24618589
Drug: GC1008 (fresolimumab)
RxNorm normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GC1008 (fresolimumab) at doses of 0.1, 0.3, 1, 3, 10, or 15 mg/kg administered intravenously on days 0, 28, 42, and 56, followed by Extended Treatment of 4 doses every 2 weeks for up to 2 additional courses.
Trial: 24619017
Drug: Accelerated partial
RxNorm normalized name: rosin partially dimerized glycerol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated partial breast irradiation (APBI) using external beam three-dimensional conformal radiotherapy (3D-CRT) at a total dose of 36.9 Gy (nine fractions of 4.1 Gy b.i.d.)
Trial: 24619321
Drug: Combined arm
RxNorm normalized name: ARM-210
DrugBank: ARM-210 (DB16944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined arm (behavioral and medication management)
Trial: 24619321
Drug: Medication management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication management arm
Trial: 24622344
Drug: Pedometer +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pedometer + weekly prompts + SDT grounded texts
Trial: 24622344
Drug: Pedometer +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pedometer + weekly prompts
Trial: 24622806
Drug: Milk diet
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk diet (semiskimmed milk-based diet, 1700 mg Ca/d)
Trial: 24622806
Drug: Cheese diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cheese diet (semihard cow-cheese-based diet, 1700 mg Ca/d)
Trial: 24622806
Drug: Control diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control diet (nondairy diet, ~500 mg Ca/d)
Trial: 24623282
Drug: Vismodegib, 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vismodegib, 150 mg/d for a mean of 18.0 months (range, 11-24 months)
Trial: 24623833
Drug: Maraviroc monotherapy
RxNorm normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maraviroc monotherapy for 10 days
Trial: 24624090
Drug: Ephedrine (0.8-3.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine (0.8-3.3 mg/min)
Trial: 24624090
Drug: Phenylephrine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine infusion (0.02-0.07 mg/min)
Trial: 24624979
Drug: Disease-modifying therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disease-modifying therapy (DMT) compliance measured through pharmacy drug shipment records.
Trial: 24625556
Drug: Dose-dense chemoimmunotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-dense chemoimmunotherapy with central nervous system prophylaxis
Trial: 24625687
Drug: Interferon beta-1a
RxNorm normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon beta-1a 44 mcg subcutaneously (IFN β-1a SC) three times weekly
Trial: 24626872
Drug: Aztreonam for
RxNorm normalized name: Aztreonam for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aztreonam for inhalation solution
Trial: 29579617
Drug: Conventional cardiac
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional cardiac resynchronization therapy (CRT)
Trial: 24627529
Drug: NT-proBNP cut-off
RxNorm normalized name: Off! Explore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NT-proBNP cut-off value of 600 pg·mL(-1)
Trial: 24627529
Drug: NT-proBNP ≥
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NT-proBNP ≥ 600 pg·mL(-1)
Trial: 24628963
Drug: XELBEVOCT regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XELBEVOCT regimen (octreotide LAR 20 mg monthly, metronomic capecitabine 2000 mg daily, intravenous bevacizumab 5 mg/kg every 2 weeks for 9 months)
Trial: 24634374
Drug: Adoptive transfer
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes with DC vaccination (n = 10)
Trial: 24634374
Drug: Adoptive transfer
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes without DC vaccination (n = 3)
Trial: 24635447
Drug: Prolotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolotherapy with hypertonic dextrose and morrhuate sodium injections (15% dextrose and 5% morrhuate sodium) at peri-articular tendon and ligament insertions, and a single intra-articular injection of 6 mL 25% dextrose.
Trial: 24635447
Drug: Prolotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolotherapy with hypertonic dextrose and morrhuate sodium injections.
Trial: 24635447
Drug: Postprocedure opioid
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postprocedure opioid medication use.
Trial: 24635447
Drug: Participant satisfaction
RxNorm normalized name: OCTINOXATE 0.28 g in 4 g TOPICAL LIPSTICK [SATIN SATISFACTION LIP COLOR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participant satisfaction after prolotherapy injections.
Trial: 24637635
Drug: Bevacizumab (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (15 mg/kg) administered before tumor resection
Trial: 24637635
Drug: Bevacizumab pharmacokinetics
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab pharmacokinetics
Trial: 24637689
Drug: Danoprevir and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danoprevir and mericitabine combination treatment
Trial: 24638072
Drug: Moderately intensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderately intensive chemotherapy for HIV-1 related lymphoma
Trial: 24641955
Drug: Immunosuppressive agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunosuppressive agents (cyclophosphamide, glucocorticosteroids, mycophenolate mofetil)
Trial: 24642016
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of autologous bone marrow-derived total nucleated cells (TNC)
Trial: 24642016
Drug: MRI assessment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRI assessment at 6 months post-therapy